These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37345898)

  • 41. An NF-κB Transcription-Factor-Dependent Lineage-Specific Transcriptional Program Promotes Regulatory T Cell Identity and Function.
    Oh H; Grinberg-Bleyer Y; Liao W; Maloney D; Wang P; Wu Z; Wang J; Bhatt DM; Heise N; Schmid RM; Hayden MS; Klein U; Rabadan R; Ghosh S
    Immunity; 2017 Sep; 47(3):450-465.e5. PubMed ID: 28889947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment Study.
    Buhrmann C; Shayan P; Brockmueller A; Shakibaei M
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32962102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
    Yano H; Andrews LP; Workman CJ; Vignali DAA
    Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The m6A reader YTHDF2 alleviates the inflammatory response by inhibiting IL-6R/JAK2/STAT1 pathway-mediated high-mobility group box-1 release.
    Zeng Z; Lan Y; Zhang L; Chen Y; Gong Y; Zuo F; Li J; Luo G; Peng Y; Yuan Z
    Burns Trauma; 2023; 11():tkad023. PubMed ID: 38026444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
    Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
    Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NF-κB: Governing Macrophages in Cancer.
    Cornice J; Verzella D; Arboretto P; Vecchiotti D; Capece D; Zazzeroni F; Franzoso G
    Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
    Wang H; Cai H; Li L
    Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. METTL3 Regulates Osteoblast Differentiation and Inflammatory Response via Smad Signaling and MAPK Signaling.
    Zhang Y; Gu X; Li D; Cai L; Xu Q
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892163
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
    Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
    Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy.
    Jeon SH; Kang M; Jeon M; Chung Y; Kim AR; Lee YJ; Kim ES; Nam H; Park J; Lee JY; Shin EC; Seo SI; Park SH
    Clin Cancer Res; 2023 May; 29(9):1794-1806. PubMed ID: 36716293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting Neuropilin-1 Suppresses the Stability of CD4
    Gao YL; Wang CX; Wang ZY; Li WJ; Liu YC; Shou ST; Chai YF
    Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33139385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.
    Riaz F; Huang Z; Pan F
    Front Immunol; 2023; 14():1280741. PubMed ID: 37936703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CARD11 regulates the thymic Treg development in an NF-κB-independent manner.
    Hu Y; Han L; Xu W; Li T; Zhao Q; Lu W; Sun J; Wang Y
    Front Immunol; 2024; 15():1364957. PubMed ID: 38650932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. YTHDF2 protein stabilization by the deubiquitinase OTUB1 promotes prostate cancer cell proliferation via PRSS8 mRNA degradation.
    Zhao X; Lv S; Li N; Zou Q; Sun L; Song T
    J Biol Chem; 2024 Apr; 300(4):107152. PubMed ID: 38462165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
    Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
    Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
    [No Abstract]   [Full Text] [Related]  

  • 60. SUMOylation of the m6A reader YTHDF2 by PIAS1 promotes viral RNA decay to restrict EBV replication.
    Sugiokto FG; Saiada F; Zhang K; Li R
    mBio; 2024 Feb; 15(2):e0316823. PubMed ID: 38236021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.